Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center of China
Sponsor: Peking Union Medical College + Peking University Hospital of Stomatology
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
ORR
Time frame: ORR at the end of Cycle 2 (each cycle is 21 days)
Secondary Endpoints
MPR;
R0 resection rate;
Facial nerve protection rate
Eligibility Criteria
Inclusion Criteria: * Patients with histopathologic diagnosis of salivary gland carcinoma * The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining. * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment; * Age 18 or older - no upper limit; * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures; ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions: ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation/operation; ⑩Ability to comply with research visit schedules and other programmatic requirements. Exclusion Criteria: * Known hypersensiti…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →